CDK2 and breast cancer: More importantly, we revealed that high MITH indicated cell cycle pathway activation in HR+ breast cancers and such activation was mainly due to the upregulation of Cyclin E/CDK2, which was an important mechanism of CDK4/6 inhibitor resistance49.